Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an igf-dependent mechanism. Role of serine proteases

Growth Regulation

Volumn 6, Issue 3, 1996, Pages 130-136

  Angelloz Nicoud, P ^a   Hard, L ^a   Binoux, M ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cell proliferation, prostate adenocarcinoma; Igf binding proteins (igfbps); Insulin like growth factors (igfs); Serine protease inhibitors

Indexed keywords

PLASMIN; PLASMINOGEN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; UROKINASE;

ARTICLE; BINDING AFFINITY; CARCINOMA CELL; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; ELECTROPHORESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PROSTATE CARCINOMA; PROTEIN DEGRADATION;

ADENOCARCINOMA; ANTIBODIES; CELL DIVISION; CELL LINE; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR II; KINETICS; MALE; PLASMIN; PLASMINOGEN; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS; SERINE PROTEINASE INHIBITORS; SULFONES; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029845524     PISSN: 0956523X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kaighn M E, Narayan K S, Ohnuki Y, Lechner J F, Jones L W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23.
2. Rechler M M, Brown A L. Insulin-like growth factor binding proteins: gene structure and expression. Growth Regulation 1992; 2: 55-68.
3. Clemmons D R, Jones J I, Busby W H, Wright G. Role of insulin-like growth factor binding proteins in modifying IGF actions. Ann NY Acad Sci 1993; 692: 10-21.
4. Kaicer E, Blat C, Harel L. IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 1991; 4: 231-237.
5. Angelloz-Nicoud P, Binoux M. Automne regulation of cell proliferation by the IGF and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology (in press).
6. Liu L, Delbé J, Blat C, Zapf J, Harel L. Insulin-like growth factor binding protein-3 (IGFBP-3), an inhibitor of serum growth factors other than IGF-I and -II. J Cell Physiol 1992; 153: 15-21.
7. Kaicer E, Blat C, Imbenotte J et al. IGF binding protein-3 secreted by prostate adenocarcinoma cells (PC-3): differential effect on PC-3 and normal prostate cell growth. Growth Regulation 1993; 3: 180-189.
8. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-59.
9. Binoux M, Lassarre C, Gourmelen M. Specific assay for insulin-like growth factor (IGF) II using the IGF binding proteins extracted from human cerebrospinal fluid. J Clin Endocrinol Metab 1986; 63: 1151-1155.
10. Hossenlopp P, Binoux M. Use of peptide ligand for the detection of binding proteins by Western ligand blotting. In: Dunbar B S, ed. Protein blotting: a practical approach. Oxford: Oxford University Press, 1994: 169-186.
11. Lalou C, Binoux M. Evidence that limited proteolysis of insulin-like growth factor binding protein-3 (IGFBP-3) occurs in the normal state outside of the bloodstream. Regul Pept 1993; 48: 179-188.
12. Lassarre C, Binoux M. Insulin-like growth factor binding protein-3 is functionally altered in pregnancy . plasma. Endocrinology 1994; 134: 1254-1262.
13. Blat C, Villaudy J, Binoux M. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 1994; 93: 2286-2290.
14. Conover C A. Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism. Endocrinology 1992; 130: 3191-3199.
15. Conover C A, Ronk M, Lombana F, Powell D R. Structural and biological characterization of bovine insulin-like growth factor binding protein-3. Endocrinology 1990; 127: 2795-2803.
16. Bashkin P, Doctrow S, Klagsbrun M, Svahn C, Folkman J, Vlodavsky I. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989; 28: 1737-1743.
17. Sato Y, Rifkin D B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-llike molecule by plasmin during co-culture. J Cell Biol 1989; 109: 309-315.
18. Sporn M B, Roberts A B. Autocrine growth factors and cancer. Nature 1985; 313: 745-747.
19. Hoosein N M, Boyd D D, Hollas W J, Mazar A, Henkin J, Chung L W K. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 1991; 3: 255-264.
20. Stearns M E, Wang M, Stearns M. Proteases and invasion by metastatic tumor cells: clinical implications for prostate cancer. Int J Oncol 1994; 4: 1013-1023.